MedTrace Logo

Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy

NCT02955641 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-04-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and need for prescribing anti-inflammatory topical drops to patients undergoing laser peripheral iridotomy.

Conditions

  • Glaucoma, Closed-Angle
  • Glaucoma, Narrow-Angle
  • Glaucoma, Angle-Closure

Interventions

DRUG

Dexamethasone Disodium Phosphate 0.1%

four drops a day for four days after LPI treatment

DRUG

Nepafenac 0.1%

four drops a day for four days after LPI treatment

DRUG

Hydroxyethylcellulose 0.19%

four drops a day for four days after LPI treatment

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Ari Leshno, MD · Sheba Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2018-11-30
Completion
2019-11-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02955641 on ClinicalTrials.gov